uploads///Graph

Meningitis Vaccines Portfolio Could Boost GSK’s Revenues in 2018

By

Feb. 1 2018, Updated 9:01 a.m. ET

Meningitis vaccines portfolio

In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 298 million pounds from the sale of its meningitis vaccines, which is year-over-year (or YoY) growth of 31% on a reported basis and 25% on a constant exchange rate (or CER) basis. The company’s meningitis vaccines portfolio witnessed sales worth 143 million pounds in the US market in 3Q17, which is YoY growth of 44% on a reported basis and 36% on a CER basis. GlaxoSmithKline earned revenues close to 103 million pounds from the sale of meningitis vaccines in Europe in 3Q17, which is a YoY rise of 34% on a reported basis and 30% on a CER basis. Further, in 3Q17, the company saw meningitis vaccine sales close to 52 million pounds in international markets, which is a YoY rise of 2% on a reported basis and a drop of 4% on a CER basis. GlaxoSmithKline, Merck (MRK), Sanofi (SNY), and Pfizer (PFE) are the four leading vaccine segment players in the world.

GlaxoSmithKline accounts for around 0.91% of the Vanguard FTSE All-World ex-US ETF’s (VEU) total portfolio holdings.

Article continues below advertisement

Bexsero growth trends

The robust performance of GlaxoSmithKline’s meningitis vaccines was mainly driven by the robust uptake of the Bexsero vaccine in Europe as well as in the US in 3Q17. Bexsero witnessed total revenues close to 176 million pounds in 3Q17, which is YoY growth of 32% on a reported basis and 26% on a CER basis. The vaccine witnessed sales worth 69 million pounds in the US market in 3Q17, which is YoY growth of 30% on a reported basis and 23% on a CER basis. The launch of new immunization programs and regional tenders as well as private market sales in Europe boosted Bexsero’s sales to 94 million pounds in the continent, which is YoY growth of 36% on a reported basis and 32% on a CER basis. GlaxoSmithKline earned revenues close to 13 million pounds from the sale of Bexsero in international markets in 3Q17, which is a YoY rise of 18% on a reported basis and 9% on a CER basis.

In the next article, we will discuss GlaxoSmithKline’s transaction with Novartis and its impact on the former’s vaccine portfolio in greater detail.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.